Results 71 to 80 of about 30,839 (241)

Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells

Biomolecular Concepts, 2021
The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome, Gohari Ladan Hosseini, Barati Mahmood, Safa Majid   +3 more
doaj   +1 more source

BCR-ABL Tyrosine Kinase Domain Mutations Combinations Affects Imat inib Resistence in Chronic Phase Chronic Myelogenous Leukemia [PDF]

, 2019
Background: Chronic myelogenous leukemia is a myeloproliferative disease, due to reciprocal translocations of chromosome 9 and 22, resulting to Bcr-Abl fusion gene.
Amrita P N A, Endang Joewarini, Siprianus Ugroseno Yudho Bintoro, Soebandiri S, Suryohusodo P   +4 more
core  

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

α‐Synuclein in Parkinson's Disease: From Bench to Bedside

Medicinal Research Reviews, Volume 45, Issue 3, Page 909-946, May 2025.
ABSTRACT α‐Synuclein (α‐syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune‐inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α‐syn accumulates in neuronal and non‐neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells ...
Gabriele Bellini, Vanessa D'Antongiovanni, Giovanni Palermo, Luca Antonioli, Matteo Fornai, Roberto Ceravolo, Nunzia Bernardini, Pascal Derkinderen, Carolina Pellegrini   +8 more
wiley   +1 more source

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2015
Objective: To evaluate trends in mortality among adults with myeloid leukemia in the Vale do Paraíba, State of São Paulo. Methods: Data from the Brazilian National Health Service database DATASUS provided the number of deaths caused by myeloid leukemia ...
Fernando Callera, Alexandra Fernandes Callera, Evandro Secchi Rosa   +2 more
doaj   +1 more source

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]

, 1991
Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard), Hagemeijer, A. (Anne), Plas, D. (D.) van der   +2 more
core   +1 more source

Chlorogenic Acid: An In‐Depth Review of Its Effectiveness in Cancer Treatment

Cancer Nexus, Volume 1, Issue 1, April 2025.
ABSTRACT Cancer remains a formidable global health challenge. Owing to the unsatisfactory curative effects and severe side effects, it is urgent to explore safer and more effective therapeutic alternatives and drugs. Chlorogenic acid (CGA), a natural polyphenol, has emerged as a promising candidate for cancer therapy due to its multiple functions and ...
Bin Wang, Na Yin, Xinrui Liu, Yang Bai, Yue Cao, Ziqian Wang, Shiqi Bai, Shaopeng Zhang, Wanying Li, Yinghui Wang   +9 more
wiley   +1 more source

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2010
Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source

A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone [PDF]

, 1996
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years ...
Geurts van Kessel, A.H.M. (Ad), Haanen, C. (C.), Hagemeÿer, A. (A.), Mandigers, C., Mensink, E.J.B.M. (Ewald), Plas, D. (D.) van der, Witte, T. de   +6 more
core   +1 more source

Advances in reversible covalent kinase inhibitors

Medicinal Research Reviews, Volume 45, Issue 2, Page 629-653, March 2025.
Abstract Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects.
Zheng Zhao, Philip E. Bourne
wiley   +1 more source